Vitasora Raises $4M Nearly Triple Its Target as Billings Surge 70% in 2 Months
Vitasora secures $4.0 million placement, nearly triple original target
Vitasora Health has closed a $4.0 million placement to sophisticated and institutional investors, approximately 2.7 times its original $1.5 million target. The oversubscription reflects strong market demand for the AI-powered connected care provider’s commercial growth story.
The placement comprises 400 million new shares at $0.01 per share, representing an 11% discount to the 15-day volume-weighted average price (VWAP). Shares will be issued under the company’s existing placement capacity pursuant to ASX Listing Rules 7.1 and 7.1A, requiring no shareholder approval.
The significant oversubscription signals institutional and sophisticated investor confidence in Vitasora’s commercialisation pathway and the scalability of its vCare electronic medical records (EMR) platform. For a company that targeted $1.5 million and received commitments for $4.0 million, the result validates both the strategic direction and execution capabilities of management.
When big ASX news breaks, our subscribers know first
$3.0 million cornerstone from private investor Bob Peters anchors the raise
A $3.0 million commitment from private investor Mr Bob Peters through Peters Investments formed the cornerstone of the placement. Following allotment, Mr Peters is expected to become a substantial holder in the company.
The Board characterised the investment as “a strong endorsement of the Company’s strategy, its strong US-leadership team, vCare EMR platform and its pathway to cashflow breakeven.” The single large private investor commitment provides register stability and aligns a significant new stakeholder with the company’s growth trajectory.
In addition to the placement, directors intend to subscribe for up to $250,000 of new shares on the same terms, subject to shareholder approval under ASX Listing Rule 10.11 at a forthcoming general meeting. The director participation further aligns Board interests with shareholders as Vitasora enters its next growth phase.
What is a cornerstone investment and why does it matter?
A cornerstone investor commits to a significant portion of a capital raise before it opens to other market participants. This provides certainty of funding and often signals confidence to the broader market, potentially attracting follow-on institutional interest.
In Vitasora’s case, $3.0 million of the $4.0 million total came from a single private investor, reducing placement execution risk and providing the company with strong register support. For small-cap ASX companies, cornerstone commitments de-risk capital raises by securing a substantial base allocation, allowing management to focus on execution rather than ongoing capital market engagement.
The Peters cornerstone also serves as a validation signal to other investors. When a sophisticated high-net-worth individual commits 75% of a capital raise, it suggests detailed due diligence and conviction in the underlying investment thesis, which can catalyse broader market re-rating.
Monthly billings accelerate 70% since April
Vitasora’s commercial momentum has accelerated throughout the June quarter. Average daily billings across the company’s combined Ceras and vCare programmes increased from US$7,321 in April 2026 to US$9,500 in May 2026, representing 30% month-on-month growth. June 2026 month-to-date billings reached US$12,412 per day, a further 31% increase.
The compounding growth trajectory demonstrates commercial traction for the vCare platform. Over the five most recent billing days, average daily billings reached US$13,262, approximately 81% above the April average. This represents a 70% increase in average daily billings since April 2026.
The vCare platform launch in April 2026 had already driven patient enrolments to 469 that month, nearly double the February-March average, establishing the commercial base from which the June billing acceleration has compounded.
| Period | Average Daily Billings (US$) | Growth |
|---|---|---|
| April 2026 | $7,321 | — |
| May 2026 | $9,500 | +30% MoM |
| June 2026 MTD | $12,412 | +31% MoM |
| Last 5 billing days | $13,262 | +81% vs April |
Billings reflect combined activity across both Ceras and vCare programmes. The company noted that April and May metrics are based on billable care minutes delivered, with final fee-for-service revenue derived from reimbursable CPT codes generated from these activities. Validation of this process is currently underway following the vCare transition.
The accelerating billing trajectory supports Vitasora’s stated pathway to cashflow breakeven and demonstrates commercial traction for the vCare platform in the US market.
Use of funds targets commercialisation scale-up
Net proceeds from the placement will be allocated to support Vitasora’s commercialisation and scale-up of patient onboarding via the vCare EMR platform. The company outlined four use of funds categories:
- Patient Management and Account Management
- Sales, business development, and marketing
- vCare Platform Enhancement & Roll-out
- Working capital and offer-related costs
Capital allocation prioritises revenue-generating activities and platform scalability rather than research and development expenditure. This deployment strategy aligns with the company’s stated H2 CY2026 cashflow breakeven target, focusing resources on commercial execution and customer acquisition.
Pathway to cashflow breakeven in H2 CY2026
Vitasora expects monthly business-as-usual cashflow breakeven to occur during H2 of CY2026. The company is now funded through to that milestone following the $4.0 million placement.
This represents a de-risking event for shareholders. With sufficient capital to reach breakeven, no further dilution is expected before the company achieves cashflow positive operations, assuming milestones are met. The funded runway shifts investor focus from capital raising to execution delivery, with commercial performance metrics becoming the primary measure of progress.
Management and Board commentary
CEO Marjan Mikel framed the raise as validation of both strategy and execution capabilities:
CEO Marjan Mikel
“This is a significant milestone for Vitasora. We sought $1.5 million and closed $4.0 million, anchored by Bob Peters’ $3.0 million investment. The raise validates our strategy, our platform and our execution. With billings accelerating, vCare scaling strongly, and a high-calibre U.S. team in place, we are funded through to monthly cashflow breakeven and focused on delivering growth.”
Non-Executive Chairman Nicholas Smedley emphasised the significance of both the cornerstone investment and director participation:
Non-Executive Chairman Nicholas Smedley
“Securing a $3.0 million cornerstone commitment from a private investor of Bob Peters’ calibre, alongside the Board’s intention to invest on the same terms, is a powerful statement of confidence in Vitasora’s strategy and execution. The Company asked the market for $1.5 million and was met with demand of $4.0 million. With the balance sheet now set, the Board’s priority is disciplined delivery of the growth plan.”
Both statements position the oversubscribed raise as market validation of Vitasora’s commercial progress and strategic direction.
Key dates for the placement
The company provided an indicative timetable for settlement and allotment of new shares. The timetable remains subject to change at the company’s discretion, subject to compliance with applicable laws and ASX Listing Rules.
- Trading halt lifted: Thursday, 11 June 2026
- Settlement of new shares: Monday, 15 June 2026
- Allotment and normal trading: Wednesday, 17 June 2026
- General meeting for director participation: To be confirmed
New shares will commence trading on Wednesday, 17 June 2026 following allotment. The general meeting to approve director participation of up to $250,000 will be convened in due course, with further details to be set out in the Notice of Meeting.
The next major ASX story will hit our subscribers first
Investment outlook
Vitasora has secured $4.0 million in capital, approximately 2.7 times its original target, anchored by a $3.0 million cornerstone from private investor Bob Peters. Monthly billings have accelerated 70% since April 2026, demonstrating commercial traction for the vCare platform. The company is now funded through to its expected H2 CY2026 monthly cashflow breakeven milestone.
Near-term catalysts include shareholder approval of director participation, continued billing growth updates, and delivery of the H2 CY2026 breakeven milestone. With capital secured and commercial momentum building, the investment thesis hinges on management’s ability to convert accelerating billing growth into sustainable cashflow positive operations.
The company’s focus shifts to execution and delivery against its stated growth plan. Register stability from the Peters cornerstone and director alignment through proposed participation provide structural support as Vitasora scales patient onboarding and platform adoption in the US market.
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors receiving FREE real-time ASX healthcare alerts with in-depth analysis delivered within minutes of market announcements. Click the “Free Alerts” button at Big News Blast to get breaking news the moment it drops, with expert coverage already done for you.